New ALS impact from ImStar
VANCOUVER, British Columbia ”Biotechnology company ImStar Therapeutics has announced the selection of IMS-088 as its lead drug candidate for treating amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. In connection with this move, the company has also filed a patent application with the United States Patent and Trademark Office covering novel withanolide therapeutics.
That's where ImStar's IMS-088 comes in. The compound is the result of a discovery by Dr. Jean-Pierre Julien, co-founder and chief scientific officer at ImStar, of a new target for ALS: TDP-43 associated NF-kB activation (TANA). TAR DNA-binding protein 43 (TDP-43) was recently identified as the primary disease-associated protein in ALS. While the protein normally regulates gene expression and is found in the nucleus of cells, it is misprocessed in ALS-a